高级检索
当前位置: 首页 > 详情页

HBV resistant to lamivudine: Experimental and clinical studies

| 认领 | 导出 |

文献详情

资源类型:
机构: [1]Department of Clinical Laboratory Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China [2]Institution of Molecular Biology Diagnostic Center, First Military Medical University, Guangzhou 510515, China
出处:
ISSN:

关键词: HBeAg seroconversion Lamivudine Microplate hybridization Tyr-Met-Asn-Asp mutants

摘要:
Objective: To identify the impact of lamivudine on HBV e antigen (HBeAg) seroconversion and HBV DNA level, and the appearance of Tyr-Met-Asn-Asp (YMDD) resistants. Methods: Forty-seven hepatitis B patients were treated with oral lamivudine. ALT level and HBeAg were detected in the treatment on the zero, 3rd, 6th and 9th month respectively. The levels of HBV DNA and YMDD resistants were analyzed with PCR microplate hybridization-ELISA. Results: After 9 months of treatment, HBV DNA became negative and ALT level was normal in 74% patients. Among these patients, 17% patients had HBeAg converted to negative and anti-HBe antibody positive, whereas another 15% patients showed HBeAg negative. YMDD resistants appeared in 19% patients (9/47). One, three and five resistants were detected in the treatment on the 3rd, 6th and 9th month respectively. Conclusions: Most HBV DNA in serum became negative after 9 months of treatment, and the rate of HBeAg seroconversion was 17% (HBV DNA level was lower than 100 pg/ml before treatment). YMDD resistants appeared in 19% patients.

语种:
中科院(CAS)分区:
出版当年[2001]版:
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 胃肠肝病学
第一作者:
第一作者机构: [1]Department of Clinical Laboratory Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号